Streetbeat News

Revenues

DRQ

Dril-Quip (NYSE:DRQ) reported Q4 2023 earnings of $0.04 per share, missing the consensus estimate of $0.18 by 77.78%. However, their quarterly sales of $126.34M exceeded the estimate of $118.50M by 6.62%, marking a 30.50% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:16 pm

ACB

CRLBF

CURLF

GTBIF

HITI

TCNNF

TLRY

Following Germany's decision to legalize limited cannabis possession, U.S. and Canadian cannabis stocks like Curaleaf Holdings, Trulieve Cannabis Corp., Green Thumb Industries, Cresco Labs, Tilray, and Aurora Cannabis saw movements in their stock prices. Analysts predict significant growth potential in the German market, comparing it to Florida's medical cannabis market. Companies like Tilray and Aurora Cannabis, already established in Germany, are well-positioned to benefit. Curaleaf's affiliate owns a German importer, and High Tide Inc. expressed enthusiasm about entering the German market.

Portfolio Pulse from Maureen Meehan

February 26, 2024 | 9:13 pm

TMDX

TransMedics forecasts a significant revenue increase for the full year 2024, expecting total revenue to be between $360M-$370M, which surpasses the estimated $330.227M. This projection indicates a growth of 49% to 53% compared to the previous year's revenue.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:10 pm

HIMS

Hims & Hers Health projects its Q1 2024 revenue to be between $267M and $272M, surpassing the estimated $252.548M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:09 pm

RVMD

Revolution Medicines (NASDAQ:RVMD) reported Q4 sales of $700K, missing the consensus estimate of $1.09M by 35.83%. This represents a 95.43% decrease from the same period last year, where sales were $15.33M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:06 pm

STAA

STAAR Surgical Company projects its FY24 financial outlook with net sales expected to be between $335 million to $340 million, and an Adjusted EBITDA of approximately $36 million. Adjusted EBITDA per diluted share is anticipated to be around $0.70. The forecast includes a 7% growth in EVO ICL sales in the APAC region, with a 10% increase in China, a 10% growth in the Americas including the U.S., and EMEA sales remaining steady with the previous fiscal year.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:03 pm

WDAY

Workday has reaffirmed its fiscal year 2025 subscription revenue guidance, projecting it to be between $7.725 billion and $7.775 billion.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 9:03 pm

COIN

SHIBUSD

Shiba Inu (CRYPTO: SHIB) is trading higher by 3.3% near the $0.0001-level, alongside a surge in Bitcoin and other crypto-related stocks. Coinbase shares have increased by 48% in the past month, driven by Bitcoin's rally, the approval of spot Bitcoin ETFs, and growing institutional interest. However, Coinbase experienced significant Bitcoin outflows last week.

Portfolio Pulse from Henry Khederian

February 26, 2024 | 8:50 pm

PODD

Insulet (PODD) provided its Q1 2024 and FY24 revenue growth guidance, expecting 17%-20% and 12%-17% growth respectively. The guidance accounts for a $20M-$25M shift in U.S. revenue due to accelerated pharmacy wholesaler orders ahead of a new ERP system implementation. Product line growth forecasts include a significant increase in Drug Delivery for Q1 2024. Gross margin is projected at 68%-69%, and operating margin at 13% for FY24, excluding a 60 basis point negative impact from the revenue shift.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:20 pm

ACCD

Accolade (NASDAQ:ACCD) has received mixed analyst ratings over the past quarter, with 7 analysts offering opinions ranging from bullish to bearish. Recent updates show a shift towards more positive ratings, with an average 12-month price target of $15.29, reflecting a 15.83% increase from the previous target of $13.20. Analysts from firms like Leerink Partners, Needham, and Raymond James have adjusted their ratings and price targets, indicating a generally positive outlook on Accolade's performance despite its challenges in revenue growth, net margin, and ROE compared to industry peers.

Portfolio Pulse from Benzinga Insights

February 26, 2024 | 7:01 pm